Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
To determine serum interleukin-33 (IL-33) levels and their associations with clinical parameters in patients with systemic sclerosis (SSc). Serum IL-33 levels were examined by enzyme-linked immunosorbent assay in 69 patients with SSc and 30 healthy individuals. In a retrospective longitudinal study, sera from 14 patients with SSc were analyzed (follow-up, 1-7 years). Serum IL-33 levels were elevated in SSc patients (261.7 ± 141.9 pg/ml) compared with healthy individuals (174.9 ± 72.4 pg/ml; P < 0.001). Patients with diffuse cutaneous SSc had higher levels of IL-33 (287.5 ± 146.6 pg/ml) than those with limited cutaneous SSc (221.5 ± 126.5 pg/ml; P < 0.05). Pulmonary fibrosis and decreased forced vital capacity were more commonly found in patients with elevated IL-33 levels than in those with normal IL-33 levels. IL-33 levels correlated positively with the extent of skin sclerosis, and inversely with percent predicted forced vital capacity. IL-33 levels were increased in SSc patients and correlated with the extent of skin sclerosis and the severity of pulmonary fibrosis. Therefore, IL-33 possibly plays a role in cutaneous and pulmonary fibrosis in SSc patients.
Department of Dermatology, The Jikei University School of Medicine, Minato, Tokyo, Japan.
Koichi
K
Yanaba
Ayumi
A
Yoshizaki
Yoshihide
Y
Asano
Takafumi
T
Kadono
Shinichi
S
Sato
D000293:Adolescent; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D004730:Endothelium, Vascular / Q000473:pathology; D005260:Female; D005355:Fibrosis; D006801:Humans; D000067596:Interleukin-33; D007378:Interleukins / Q000097:blood*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000473:pathology* / Q000503:physiopathology; D012189:Retrospective Studies; D012595:Scleroderma, Systemic / Q000097:blood* / Q000473:pathology* / Q000503:physiopathology; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology*; D014797:Vital Capacity / Q000502:physiology; D055815:Young Adult
C506536:IL33 protein, human; D000067596:Interleukin-33; D007378:Interleukins
J Rheumatol. 1993 Nov;20(11):1892-6
8308774
Arthritis Rheum. 1977 May;20(4):975-84
861067
FEBS Lett. 1992 May 18;302(3):231-4
1601130
Arthritis Rheum. 1994 Mar;37(3):391-4
8129794
J Rheumatol. 2006 Feb;33(2):275-84
16465658
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10913-8
18667700
Rheum Dis Clin North Am. 1996 Nov;22(4):695-708
8923591
PLoS One. 2008 Oct 06;3(10):e3331
18836528
Eur J Immunol. 2007 Oct;37(10):2779-86
17853410
Springer Semin Immunopathol. 1999;21(4):431-50
10945035
Arthritis Rheum. 1980 May;23(5):581-90
7378088
Immunity. 2005 Nov;23(5):479-90
16286016
Arthritis Rheum. 1984 Jun;27(6):645-53
6375682
Clin Exp Immunol. 1990 Sep;81(3):368-72
2397608
Ann Rheum Dis. 2010 Mar;69(3):598-605
19778913
J Rheumatol. 1988 Feb;15(2):202-5
3361530
Arthritis Rheum. 2009 Mar;60(3):738-49
19248109
Arthritis Rheum. 1988 Feb;31(2):196-203
3348823
Curr Opin Rheumatol. 1999 Nov;11(6):503-7
10551675
Arthritis Rheum. 1992 Jan;35(1):67-72
1731816
Eur J Clin Invest. 1988 Feb;18(1):9-17
3130266
J Rheumatol. 1997 Feb;24(2):328-32
9034992
Br J Dermatol. 1998 Oct;139(4):639-48
9892907
Immunol Today. 2000 May;21(5):206-9
10782049
Clin Exp Immunol. 1999 Apr;116(1):164-8
10209521